Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard D Kim

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
JCO Precision Oncology|January 8, 2025
Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative ResectionJames Yu, Aiwu Ruth He, Mahmoud Ouf, et al.
Sleep|June 30, 2015
An Economic Evaluation of Home Versus Laboratory-Based Diagnosis of Obstructive Sleep ApneaRichard D Kim, Vishesh K Kapur, Julie Redline-Bruch, et al.
Journal of Medical Imaging and Radiation Oncology|May 10, 2020
CT-based radiomic features to predict pathological response in rectal cancer: A retrospective cohort studyZhigang Yuan, Marissa Frazer, Geoffrey G Zhang, et al.
Future Oncology (London, England)|July 21, 2020
Modeling precision genomic-based radiation dose response in rectal cancerZhigang Yuan, Marissa Frazer, Kamran A Ahmed, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2020
Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancerRichard D Kim, Shannon McDonough, Anthony B El-Khoueiry, et al.
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|May 5, 2021
Pretreatment CT and PET radiomics predicting rectal cancer patients in response to neoadjuvant chemoradiotherapyZhigang Yuan, Marissa Frazer, Anupam Rishi, et al.
Journal of Vascular and Interventional Radiology : JVIR|July 26, 2018
Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective StudyAlexandra Gangi, Jehan Shah, Nathan Hatfield, et al.
Cancer Discovery|October 3, 2019
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular CarcinomaMegan A Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin, et al.
Hepatology (Baltimore, Md.)|November 10, 2025
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinomaAnthony B El-Khoueiry, Richard D Kim, William P Harris, et al.
Cancers|June 13, 2025
Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant TherapyJames Yu, Jose M Laborde, Robin Park, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
JCO Precision Oncology|January 8, 2025
Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative ResectionJames Yu, Aiwu Ruth He, Mahmoud Ouf, et al.
Sleep|June 30, 2015
An Economic Evaluation of Home Versus Laboratory-Based Diagnosis of Obstructive Sleep ApneaRichard D Kim, Vishesh K Kapur, Julie Redline-Bruch, et al.
Journal of Medical Imaging and Radiation Oncology|May 10, 2020
CT-based radiomic features to predict pathological response in rectal cancer: A retrospective cohort studyZhigang Yuan, Marissa Frazer, Geoffrey G Zhang, et al.
Future Oncology (London, England)|July 21, 2020
Modeling precision genomic-based radiation dose response in rectal cancerZhigang Yuan, Marissa Frazer, Kamran A Ahmed, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2020
Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancerRichard D Kim, Shannon McDonough, Anthony B El-Khoueiry, et al.
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|May 5, 2021
Pretreatment CT and PET radiomics predicting rectal cancer patients in response to neoadjuvant chemoradiotherapyZhigang Yuan, Marissa Frazer, Anupam Rishi, et al.
Journal of Vascular and Interventional Radiology : JVIR|July 26, 2018
Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective StudyAlexandra Gangi, Jehan Shah, Nathan Hatfield, et al.
Cancer Discovery|October 3, 2019
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular CarcinomaMegan A Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin, et al.
Hepatology (Baltimore, Md.)|November 10, 2025
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinomaAnthony B El-Khoueiry, Richard D Kim, William P Harris, et al.
Cancers|June 13, 2025
Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant TherapyJames Yu, Jose M Laborde, Robin Park, et al.
Pageof 6